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Leprosy, an infectious disease caused by Mycobacterium leprae, affects millions of
people worldwide. However, little is known regarding its molecular pathophysiological
mechanisms. In this study, a comprehensive assessment of human mRNA was
performed on leprosy skin lesions by using DNA chip microarrays, which included the
entire spectrum of the disease along with its reactional states. Sixty-six samples from
leprotic lesions (10TT, 10BT, 10BB, 10BL, 4LL, 14R1, and 10R2) and nine skin biopsies
from healthy individuals were used as controls (CC) (ages ranged from 06 to 83 years,
48 were male and 29 female). The evaluation identified 1580 differentially expressed
mRNAs [Fold Change (FC) ≥ 2.0, p ≤ 0.05] in diseased lesions vs. healthy controls.
Some of these genes were observed in all forms of the disease (CD2, CD27, chit1,
FA2H, FAM26F, GZMB, MMP9, SLAMF7, UBD) and others were exclusive to reactional
forms (Type “1” reaction: GPNMB, IL1B, MICAL2, FOXQ1; Type “2” reaction: AKR1B10,
FAM180B, FOXQ1, NNMT, NR1D1, PTX3, TNFRSF25). In literature, these mRNAs have
been associated with numerous pathophysiological processes and signaling pathways
and are present in a large number of diseases. The role of these mRNAs maybe studied
in the context of developing new diagnostic markers and therapeutic targets for leprosy.
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INTRODUCTION
Leprosy is a chronic infectious disease caused by Mycobacterium leprae, which affects millions of
people worldwide. It is estimated that hundreds of thousands of new cases are diagnosed each year,
mostly in India and Brazil, among other countries in South America, Asia, and Africa, in addition
to sporadic cases in Europe and North America (World Health Organization, 2014).M. leprae is an
obligate intracellular parasite with slow replication, a long incubation period, and a small number of
genes that control its metabolism (Akama et al., 2009). These characteristics make the host-parasite
interaction in leprosy unique, resulting in a chronic spectral long-lasting disease, with various
clinical presentations and of great challenge to clinical practice. Ridley and Jopling’s classification
(R&J) divides leprosy into two polar forms, tuberculoid (TT) and lepromatous (LL), and a
borderline group divided into three subgroups: borderline-tuberculoid (BT), borderline-borderline
(BB), and borderline-lepromatous (BL), according to clinical, bacilloscopic, and histopathological
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criteria (Ridley and Jopling, 1966). There may also be two types
of reactional episodes, named type 1 reaction (R1) and type 2
reaction (R2), which are sometimes intense and destructive and
can occur during disease progression (Hastings et al., 1988).
The reactional episodes are the main cause of tissue destruction,
particularly nerves, which may result in important sequels and
permanent incapacities.
Despite being a long-known disease, there are still major
gaps in knowledge about the pathophysiological mechanisms
of leprosy (Hastings et al., 1988). Recently, genomic studies
have provided a better understanding of pathophysiological
mechanisms in several diseases leading to improved diagnosis,
prognosis, prevention, and treatment strategies (Pasic et al.,
2013). For example, transcriptional profiling of neoplasia, has
shown that tumors aremolecularly heterogeneous and has helped
identify novel genes associated with tumorigenesis and targets
with therapeutic, prognostic, or predictive potential (Sethi et al.,
2013; Lam et al., 2014). Although similar studies have been
conducted in inflammatory and infectious diseases, only few have
considered leprosy (Liu et al., 2012; França et al., 2013; Guerreiro
et al., 2013; Orlova et al., 2013; Singh et al., 2013; Mehta and Liu,
2014).
The multi-drug therapy (MDT) for leprosy treatment is
effective; however, the treatment for reactional episodes is
difficult. The drugs most commonly used (corticosteroids and
thalidomide), despite effective, are difficult to handle in the
clinical practice because they may cause important harmful side
effects such as diabetes, Cushing’s syndrome, and susceptibility
to opportunistic infection, besides the teratogenic effect of
thalidomide. Thus, there is a need of new drugs, clinically safer,
to be available for leprosy reactional episodes. A comprehensive
analysis of human mRNA expression in skin lesions of leprosy
patients was carried out in the present study by using DNA
chip microarrays which included the entire spectrum of the
disease and its reactional forms. The objective was to investigate
possible molecular mediators involved in pathophysiological
mechanisms of leprosy and to identify biomarkers that could be
used as predictive markers of reactions, or contribute to novel
therapeutic strategies.
MATERIALS AND METHODS
Study Design, Sample Collection, and
Classification
The sequence of events for this study followed the order below
and is detailed in Figure 1. Patients who were treated at the
leprosy outpatient clinic of Lauro de Souza Lima Institute-
ILSL (Bauru, São Paulo) and the Leprosy Reference Center of
Rondonópolis (Rondonópolis, Mato Grosso) were examined by
clinical leprologists (CG, SU, and JAB) and submitted to two
biopsy procedures, after an informed consent was obtained from
the patient. One biopsy was processed for histopathological
analysis, bacilloscopy, and immunohistochemistry (IHC) and the
other was immediately stored in RNAlater R© solution (Ambion)
for further RNA extraction. The non-reactional leprosy patients
had never taken any specific leprosy treatment (MDT), or were
under any other medication at the time of diagnosis. Besides,
they did not present other diseases. In respect to the reactional
patients, some developed reactional episodes before leprosy
treatment and others presented the reactional episode during or
after the treatment. However, none of them was taking any drugs
that could interfere with the immune response (corticosteroids
or thalidomide). The histopathological exams showed leprosy
lesions, with or without reactional pattern, and absence of other
concomitant diseases. The control individuals were healthy non-
contactants of leprosy patients who were not under any drug
treatment. Supplement 1 shows all the data from patients and
controls (age, gender, R&J classification, and reactional forms).
After clinical, histopathological and bacteriological evaluation,
patients were classified according to the R&J criteria including
all leprosy forms (TT, BT, BB, BL, LL, R1, and R2) (Ridley
and Jopling, 1966; Hastings et al., 1988). Sixty-eight samples
from leprotic lesions (10TT, 10BT, 10BB, 10BL, 4LL, 14R1, and
10R2) were selected for analysis. In addition, nine skin biopsies
from healthy individuals were used as controls (CC). In order
to avoid variations in histological patterns that could interfere
with mRNA expression, samples were collected from the trunk
and limbs. Scalp, face, palmar, and plantar skin lesions were not
included in the study. The study was approved by the Ethics
Committees of the AC Camargo Hospital (No. 1535/11) and
Lauro de Souza Lima Institute-ILSL (No.03/2011).
RNA Extraction and Analysis of Quality and
Integrity
Skin biopsies stored in RNAlater R© were individually cut with
a scalpel and transferred to a tube with ceramic beads (CK28,
Bertin Technologies). QIAzol reagent (700µl, Qiagen) was added
to samples, followed by processing (homogenization and lysis)
in the Precellys24 (Bertin Technologies) apparatus (1 pulse of
10 s and incubation at 4◦C for 5min; cycle was repeated 3
times). Total RNA (including miRNA) was extracted according
to themanufacturer’s specifications (miRNeasyMini Kit, Qiagen)
by using the QIAcube apparatus (Qiagen). RNA was recovered
in 30µl of RNase-free water and quantified by using the
NanoDrop 2000 instrument (Thermo Scientific). RNA integrity
was evaluated by using the 2100 Bioanalyzer electrophoresis
apparatus (GE Healthcare Bio-Sciences). Samples with low
quality or insufficient RNA were excluded from analysis.
Hybridization of Transcripts in the
Microarray Platform
The 8X60K cDNA microarray G4858A platform used in this
study (GE Healthcare Bio-Sciences) contained 60,000 probes of
60 base pairs in length representing the entire human genome.
Total RNA was reverse transcribed, amplified, and labeled with
the fluorophores by using the Low Input AmpLabeling Kit
(Agilent Technologies, catalog number 5190-2306) following
the protocols recommended by the manufacturer (two-color,
microarray-based gene expression analysis; protocol: version 6.5,
May 2010, Agilent Technologies).
A competitive hybridization was conducted by using 200 ng
of total RNA from the samples marked with Cy5 and 200 ng of
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FIGURE 1 | Study design. Patients diagnosed with leprosy underwent two punch “5” biopsies on the border of skin lesions (A). One sample was fixed in 10%
buffered formalin for routine histological processing and sections were stained with H&E, Fite-Faraco, and immunohistochemistry (B). The second sample was fixed in
RNAlater solution for RNA extraction (C). Skin samples from nine healthy subjects were collected and processed in similarly. Samples with good RNA quality were
hybridized on microarray plates for identification of differentially expressed mRNAs (FC ≥ 2.0, p ≤ 0.05) (C). Patients were classified according to Ridley and Jopling’s
criteria (D). Differentially expressed mRNAs were identified by comparison between the various groups (E).
reference RNA (pooled RNA from cell lines) labeled with Cy3.
Thus, the fluorescence values obtained showed relative levels
of expression of each transcript in the test sample compared
to the reference sample. Use of the reference sample allowed
comparison across independent experiments (Novoradovskaya
et al., 2004).
The oligoarrays were hybridized with fluorescent targets
for 17 h at 65◦C in a hybridization oven, by using the
Hi-RPM hybridization buffer (Agilent Technologies). After
hybridization, microchips were washed to eliminate non-specific
binding and background signals, according to the manufacturer
recommendations. The arrays were then scanned by using
the Agilent Bundle Scanner (Agilent Technologies) at 3µm
resolution.
Analysis of Microarray Results
The microarray data were analyzed by using the Gene Spring
GX version 12.1 software (Agilent Technologies). Initially
Frontiers in Genetics | www.frontiersin.org 3 November 2015 | Volume 6 | Article 334
Belone et al. Expression of mRNA in Leprosy
the Control Type, Probe Name, Signal, and Feature data
were imported from Feature Extraction program (version
10.7.1, Agilent Technologies). Data was normalized by log
transformation and baseline transformation.
Once normalized, the data was filtered to eliminate the spots
with low signal, background, or saturation of hybridization.
Quality control of the data was conducted by principal
components analysis (PCA).The data was then filtered to select
only probes with evidence of expression in the samples.
The search for differentially expressed genes was performed
by comparison between all the groups. Thus, expression of the
control group was compared to all disease groups [(TT + BT
+ BB + BL + LL + R1 + R2) vs. CC], all forms of the disease
[(TT, BT, BB, BL, LL) vs. CC], all intermediate forms [(BT +
BB + BL) vs. CC], polar side [(TT + BT) vs. CC and (BL +
LL) vs. CC], and polar forms (TT vs. CC and LL vs. CC), and
the reactional forms (R1 vs. CC and R2 vs. CC). In leprosy
lesions, the polar side forms were compared among them [(TT
+ BT) vs. (BL + LL)], tuberculoid forms and non-tuberculoid
forms [(TT + BT) vs. (BB + BL + LL)] and the polar forms
among them (TT vs. LL). Similarly, the reactional forms were
compared to their respective clinical forms [(TT + BT + BB
+ BL vs. R1) and (BL + LL vs. R2)], and finally, the reactional
forms were compared with each other (R1 vs. R2). The t-test
with the Bonferroni FWER correction were used for statistical
analysis, and differentially expressed genes were considered as
those with FC ≥ 2.0 and p ≤ 0.05. Differentially expressed
genes were grouped by a hierarchical cluster unsupervised
analysis.
Validation of Differentially Expressed
mRNAs by Using Quantitative RT-PCR
Differentially expressed genes identified in the cDNAmicroarray
assay were validated by quantitative RT-PCR assay by using a
customized detection system, SyBr Green platform PCR Array R©
(Qiagen), with 88 target genes, 5 housekeeping genes, and 3
internal control genes. Validation was performed for 24 samples,
three of each group (3TT, 3BT, 3BB, 3BL, 3LL, 3R1, 3R2, and 3
controls) including both samples used in the microarray assay
and new samples.
The RNA samples were treated with DNase (RNase-
Free DNase Set kit, Qiagen) to eliminate residual genomic
DNA. Subsequently, RNA was purified and concentrated with
the RNeasy MinElute Cleanup Kit (Qiagen) according the
manufacturer’s specification. The RT2 First Strand Kit (Qiagen)
was used for cDNA synthesis. The efficiency of the reverse
transcription reaction was assessed by using a RT-PCR reaction
for GAPDH.
The ABI ViiA 7 instrument was used for real-time PCR
reactions (Applied Biosystems) following the RT2 Profiler PCR
Arrays Kit (Qiagen) protocol in combination with RT2 SYBR
Green Master mix (Qiagen).
The mRNAs were selected after expression analysis in all
comparisons. The authors chose the most up and down regulated
present in all groups, and therefore, those who were related to
the disease. Others were selected because they were differentially
expressed in particular forms of the disease or reaction.
Analysis of Quantitative RT-PCR Assays
The data quality was analyzed by using the SDS 2.3 software
(Applied Biosystems). The threshold or threshold fluorescence
intensity were adjusted in the exponential phase chart by using
either the amplification curves or amplification plots, and the Ct
values (cycle threshold) were selected for each reaction. Results
were considered acceptable if HGDC (human genomic DNA
control) samples showed amplification after cycle 35 and if
standard deviation of duplicates was Ct < 0.5.
Quantitative RT-PCR results were analyzed by using the
relative expression values obtained by comparison between the
expression level of the target gene and the control or reference
gene, internal, or normalizer housekeeping gene.
Relative expression: 2-ct (target genes)/2-ct (housekeeping).
The geNorm software that assesses the stability of the
genes and the convenience of using more than one gene and
normalize was used to select the appropriate housekeeping genes
(Vandesompele et al., 2002). Among the five genes included in
the PCR array, only three were used in the calculation the relative
expression (GAPDH, HPRT1, and RPLP0).
After calculating the relative gene expression of each sample,
the difference in expression between groups or fold change
(FC) was calculated. The mean values of normalized relative
expression of the groups were compared, and the differentially
expressed genes were considered as those with FC ≥ 2.0 and
p ≤ 0.05.
Selection and Validation of mRNAs by IHC
Fifteen of the 86 mRNAs subjected to validation by quantitative
RT-PCR, were selected for evaluation of protein expression by
immunohistochemistry (IHC). Markers that were commercially
available and validated in the literature were chosen after an
analysis similar to that used for RT-PCR validation. These
included ANGPTL4 (angiopoietin-like4, 11F6C4, mouse, 1:50,
Abcam, Cambridge, UK); BAI1 (brain-specific angiogenesis
inhibitor 1, polyclonal, rabbit, 1:800, Abcam, Cambridge, UK);
BCAT1 (branched chain amino-acid transaminase 1, cytosolic,
polyclonal, rabbit, 1:400, Abcam, Cambridge, UK); CD2
(CD2 molecule, AB75, mouse, 1:100, Novocastra, Newcastle,
UK); CD27 (CD27 molecule, EPR8569, rabbit, 1:800, Abcam,
Cambridge, UK); CD52 (CD52 molecule, HI186, mouse, 1:800,
Abcam, Cambridge, UK); EML2 (echinoderm microtubule
associated protein like 2, polyclonal, mouse, 1:500, Abcam,
Cambridge, UK); FA2H (2-hydroxylase fatty acid, polyclonal,
rabbit, 1:500, Abcam, Cambridge, UK); GZMB (granzyme B,
GZB01, mouse, 1:100, DBS, Pleasanton, USA); LIPA (lysosomal
acid lipase, polyclonal, rabbit, 1:400, Abcam, Cambridge, UK);
MMP9 (matrix metallopeptidase 9, EP1254, rabbit, 1:400,
Abcam, Cambridge, UK); NCF1 (neutrophil cytosolic factor
1, polyclonal, rabbit, 1:1000, Abcam, Cambridge, UK); PTX3
(pentraxin 3, long, MNB1, rat, 1:400, Abcam, Cambridge, UK);
SIGLEC15 (sialic acid binding Ig like lectin-15, polyclonal, rabbit,
1:400, Abcam, Cambridge, UK) and UDB (ubiquitin D EPR4370,
rabbit, 1:500, Abcam, Cambridge, UK).
IHC was performed using the indirect method with
streptavidin-biotin peroxidase (LSAB, Dako) according to
the specifications recommended by the manufacturer. The
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expression of these markers was analyzed in all common
components of the skin and also in cells that composed the
granuloma and other inflammatory infiltrates (granulomas,
neural branches, vessels, arrector pili muscle, skin appendages,
stroma, and epidermis).
Analysis of Signaling Pathways and
Cellular Processes
Ingenuity pathway analysis software (IPA) was used to better
understand the regulatory mechanisms involved in inducing
gene expression changes and their impact on diseases of interest
through interactive visual exploration of causality between
molecules and disease, function, or phenotypes.
Microarray Data Accession Number
The microarray data set has been submitted to the Gene
Expression Omnibus database at NCBI (http://www.ncbi.nlm.
nih.gov/geo/) and assigned accession number GSE74481.
RESULTS
Differentially Expressed mRNAs in the
Disease and Reactional States
Between disease and healthy controls [(TT + BT + BB + BL
+ LL + R1 + R2) vs. CC], 1580 mRNAs (756up-regulated and
824 down-regulated) were differentially expressed (Supplement
2). In clinical forms vs. CC [(TT + BT + BB + BL + LL) vs.
CC], 1145 mRNAs (628 up-regulated and 517 down-regulated)
were differentially expressed (Supplement 3 andTable 1). Among
the polar forms (TT vs. LL), 33 mRNAs (01 up-regulated and 32
down-regulated) were differentially expressed (Supplement 4). In
Supplements 5–10 are detailed all mRNAs differentially expressed
comparing TT vs. CC, LL vs. CC, T side (TT+ BT) vs. CC, L side
(BL+ LL) vs. CC, borderline forms (BT+ BB+ BL) vs. CC, and
tuberculoid forms (TT + BT) vs. non-tuberculoid (BB + BL +
LL), respectively.
In the type “1” reaction vs. its respective clinical forms [R1
vs. (TT + BT + BB + BL)], 55 mRNAs (17 up-regulated and
38 down-regulated) were differentially expressed (Supplement 11
and Table 2). In type “2” reaction vs. its respective clinical forms
[R2 vs. (BL + LL)], 25 mRNAs (15 up-regulated and 10 down-
regulated) were differentially expressed (Supplement 12 and
Table 3). When comparing the reactions (R1 vs. R2), 45 mRNAs
(33 up-regulated and 12 down-regulated) were differentially
expressed (Supplement 13 and Table 4). In Supplements 14 and
15 are detailed all mRNAs differentially expressed comparing R1
vs. CC and R2 vs. CC, respectively.
Biofunction analysis of mRNA expression revealed a large
number of canonical pathways involved with the clinical forms
and leprosy reactions. Comparison of clinical forms of the disease
with controls [(TT+ BT+ BB+ BL+ LL) vs. CC] demonstrated
that the 8 canonical pathways involved have 50% or more
dysregulated genes, related to Antigen Presentation Pathway,
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells,
and B Cell Development. Supplement 16 contains the 8 canonical
pathways and the dysregulated genes involved in those pathways.
TABLE 1 | The 10 most up or down-regulated mRNAs differentially
expressed in the microarray and RT-PCR values for validated mRNAs in
clinical forms (TT+BT+BB+BL+LL) vs. CC, FC ≥ |2| and p ≤ 0.05.
Gene symbol Regulation FC microarray FC RT-PCR
IGLL5 Up 75.7 438.8
UBD Up 57.0 80.5
GZMA Up 40.2
MMP9 Up 35.3 59.7
SLAMF7 Up 32.4 166.2
CHIT1 Up 27.1 985.3
CD2 Up 25.1 52.8
CD3G Up 21.4 31.4
FAM26F Up 20.8 25.5
ITGAL Up 20.1 99.6
PON3 Down −4.0 −3.3
SLC15A1 Down −4.1 −2.4
FGFBP1 Down −4.3 −2.5
NNAT Down −4.6
KRT6C Down −4.8 −2.2
FASN Down −4.8 −3.5
AADACL3 Down −5.3 −7.6
KLK6 Down −7.5 −4.5
FA2H Down −8.8 −3.1
FADS2 Down −9.2 −4.1
TABLE 2 | The 10 most up or down regulated mRNAs differentially
expressed in the microarray and RT-PCR values for validated mRNAs in
R1 vs. R1 related clinical forms [R1 vs. (TT+BT+BB+BL)], FC ≥ |2| and
p ≤ 0.05.
Gene symbol Regulation FC microarray FC RT-PCR
ADAMTS4 Up 2.9 3.0
NCF1 Up 2.6
BCAT1 Up 2.6
RASSF4 Up 2.3
SLC16A3 Up 2.2
C17orf96 Up 2.2
ITGB2 Up 2.2
PLAUR Up 2.2
KCNE3 Up 2.1
ALOX5 Up 2.1
GRHL2 Down −2.7
FGFR3 Down −2.7
CLDN1 Down −2.6
NMU Down −2.5
CYP2J2 Down −2.4
PPP1R14C Down −2.4
KLF5 Down −2.3
HSD11B2 Down −2.3
SCEL Down −2.2
TPD52L1 Down −2.2
In a comparison of the type 1 reaction with its respective
clinical forms [R1 vs. (TT + BT + BB + BL)], 69 canonical
pathways were identified, which play roles in Leukocyte
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TABLE 3 | The 10 most up or down-regulated mRNAs differentially
expressed in the microarray and RT-PCR values for validated mRNAs in
R2 vs. R2 related clinical forms [R2 vs. (BL+LL)], FC ≥ |2| and p ≤ 0.05.
Gene symbol Regulation FC microarray FC RT-PCR
PTX3 Up 47.6 77.6
KRT6C Up 19.5 111.5
KRT6A Up 18.7
AKR1B10 Up 17.6 17.7
IL1B Up 10.4 34.1
ANGPTL4 Up 7.3
ADAMTS4 Up 6.9 14.2
NNMT Up 4.9 2.5
GJB2 Up 4.8
MT2A Up 4.5 4.3
NR1D1 Down −6.7 −14.7
MMP9 Down −4.3
TOX2 Down −3.9 −10.6
TEF Down −3.7 −6.6
EPHB6 Down −3.3
BAI1 Down −2.9 −6.0
RAB37 Down −2.9
MFSD2A Down −2.8
TNNI2 Down −2.8
EEF2K Down −2.4
TABLE 4 | The 10 most up or down-regulated mRNAs differentially
expressed in the microarray and RT-PCR values for validated mRNAs in
R1 vs. R2, FC ≥ |2| and p ≤ 0.05.
Gene symbol Regulation FC microarray FC RT-PCR
SIGLEC15 Up 6.6 4.7
MMP9 Up 6.6 13.9
FAM180B Up 4.5
SARDH Up 4.4 5.7
TOX2 Up 4.1 8.0
CHIT1 Up 3.7 15.4
RAB37 Up 3.4
CD2 Up 3.2 3.0
CXorf65 Up 3.0
ITGAL Up 2.9 3.3
PTX3 Down −27.1 −21.4
AKR1B10 Down −11.1 −5.9
ANGPTL4 Down −6.3
GJB2 Down −4.2
NNMT Down −3.7
CD300E Down −3.7 −12.2
FAM83D Down −3.3
MDFI Down −3.3
MPZL2 Down −2.9
B3GNT5 Down −2.2
Extravasation Signaling, MSP-RON Signaling Pathway, Glioma
Invasiveness Signaling and IL-17 Signaling. Supplement 17
contains all 69 canonical pathways and their respective mRNAs.
When comparing the type 2 reactional state with the
respective clinical forms [R2 vs. (BL + LL)], 26 canonical
pathways were identified which mainly function in angiogenesis,
inhibition of matrix metalloproteases, granulocyte adhesion,
diapedesis, and leukocyte extravasation signaling. Supplement
18 contains all 26 canonical pathways and their respective
mRNAs.
RT-PCR Validation of Differentially
Expressed mRNAs in the Disease and
Reactional States
Of 77 samples used in the DNA chip microarray, 24 were
subjected to RT-PCR validation. This subgroup was represented
by three samples of each clinical form including leprosy
reactional states and controls. Supplement 19 contains a table
with the values of the 87 mRNA samples submitted to validation
by RT-PCR, comparing disease, clinical forms, reactional states
with control, reactional states with their respective clinical forms,
and between reactions. In all, 69 (79.2%) mRNAs were validated
(Supplement 19 and Figure 4).
A heterogeneous expression profile was observed. The vast
majority of these mRNAs show differential expression in
the disease and the reactional states, with either higher or
lower expression values between them (CD2, CD27, chit1,
FA2H, FAM26F, GZMB, MMP9, SLAMF7, UBD). Only a few,
however, are expressed in specific segments of the disease (type
“1” reaction: ADAMTS4, ALOX15B, FGFBP1, FOXQ1, GAL,
GPNMB, IL1B, LGMN, MICAL2, TMEM91; Type “2"reaction:
ADAMTS4, AKR1B10, ALOX15B, FAM180B, FOXQ1, GAL,
LGMN, NNMT, NR1D1, PTX3, TNFRSF25). Rare mRNAs
showed inversion in expression when reactional states were
compared to the disease, meaning that they were down-regulated
in the disease and up-regulated in the reactional forms or vice
versa (GJB2 and KRT6C).
IHC Validation of Differentially Expressed
Genes in the Disease
Evaluation of marker expression by IHC is detailed in
Supplement 20. Figures 2 and 3 consist of two images showing
the histology of the skin sample panel representing the
histological patterns of the clinical forms and reactional states,
and the expression of these markers in some forms of the
leprosy spectrum, reaction forms, and control. In summary: (1)
ANGPTL4: CC showed cytoplasmic immunostaining in neural
branches and apical granules of the inner-layer of the sweat
glands. Macrophages in TT and BT granulomas showed intense
positive staining. Weak or moderate expression was observed in
BB and R1 granulomas. Weak staining or complete absence of
staining was observed in macrophages of BL, LL, and R2. (2)
BAI1: it was expressed in neural branches and CC sweat ducts.
Granulomas in all forms and reactions lacked the expression
of BAI1. (3) BCAT1: weak expression was observed in neural
branches, sebaceous glands, and sweat glands of CC. There
was intense positivity in macrophages of TT, BT, and R1 and
moderate to strong expression in macrophages of granulomas in
BB, BL, LL, and R2. (4) CD2: expression was observed only in
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FIGURE 2 | Histological sections of skin biopsies stained with H&E and Faraco-Fite. CC showing skin and subcutaneous tissue without inflammatory process
(A, H&E x2 and B, H&E x20). In TT, there are tuberculoid granulomas with epithelioid macrophages in the center and lymphocytes at the periphery (C, H&E x2 and D,
H&E x20). In BT, the granulomas are similar to those of TT (E, H&E x2), in which granuloma involves a nerve branch (F, H&E x20). In BB, the inflammatory infiltrate is
less intense (G, H&E x2) and granulomas are less defined with lymphocytes and macrophages involving neural branches (H, H&E x20). The inflammatory infiltrate in
BL is similar to BB, but more extensive with a larger number of macrophages, lymphocytes and plasma cells (I, H&E x2 and J, H&E x20). In LL, the infiltrates are
(Continued)
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FIGURE 2 | Continued
dense, occupying all segments of the skin and subcutaneous tissue (K, H&E x2), and they consist of multivacuolated macrophages with rare permeating lymphocytes
(L, H&Ex40). In R1, granulomas are defined with little inflammatory infiltrate extending adjacent to the interstitium (M, H&E x2), and the pre-existing granulomas are
permeated by young macrophages and lymphocytes and occasionally exhibit necrosis (N, H&E x40). In R2, the inflammatory infiltrates involve all layers of the dermis
with clusters of neutrophils forming micro abscesses (O, H&E x2 and P, H&E x40). Bacilloscopy 0+ in TT sample (Q, Fite-Faraco x100) and 6+ in LL sample (R,
Faraco-Fite x100).
rare lymphocytes around vessels in the papillary dermis of CC.
In the TT, BT, and R1 forms, a large number of lymphocytes
in the periphery and within granulomas, perivascular space,
nerves, and interstitium showed expression of CD2. In BB,
BL, LL, and R2 few lymphocytes showed positivity. (5) CD27:
there were rare CD27+ lymphocytes around capillaries in the
superficial dermis of CC. In BT and TT, there were a large
number of lymphocytes distributed mainly in the periphery of
granulomas. In the BB, BL, and LL forms, there were fewer
lymphocytes and homogeneous distribution was observed in the
granulomas around the macrophages. In R1, lymphocytes were
predominantly distributed in the periphery of the granulomas
and were rare or absent in the center of reactional granulomas.
In R2, there were no CD27+ lymphocytes within the abscess
and there were a few within non-reactional granulomas. (6)
CD52: immunostaining was observed in all skin components
of CC, but rare lymphocytes around vessels in the papillary
dermis were positively stained. CD52 expression was observed
in lymphocytes surrounding granulomas, with larger numbers
of lymphocytes in the TT, BT, and R1 granulomas, as well as
lymphocytes infiltrating vessels, nerves, interstitial, arrector pili
muscle, and epidermis. In BB, BL, LL, and R2 granulomas there
were fewer CD52+ lymphocytes. (7) EML2: no expression was
observed in all CC skin components. Positivity was observed
in rare macrophages of granulomas in all forms and R1. Weak
expression was observed in macrophages of R2 (8) FA2H: in
CC intense positivity was seen in the sebaceous glands with
absence in other components. There was moderate to intense
positivity in macrophages constituting the TT granulomas and
R1. In BT, BB, BL, LL, and R2 macrophages showed weak or
moderate positivity. (9) GZMB: no expression was observed in
CC. Fine granular cytoplasmic staining was observed in rare
lymphocytes in the periphery or within the granulomas in all
forms and reactional states, with a slight predominance in the TT
group (10) LIPA: there was intense expression in the sebaceous
glands and in the secretory cells of the sweat glands of CC. In
TT, BT, and R1, moderate to severe positivity was observed in
macrophages in the center of the granuloma. Expression was
mild to moderate in macrophages of BB, BL, LL, and R2. (11)
MMP9: In CC, rare perivascular macrophages were positive. In
TT, BT, BB, BL, LL, and R1 intense expression was observed in
macrophages. In R2, there was strong positivity in macrophages
and neutrophils. Interstitial fibroblasts were positive in both
reactional states. (12) NCF1: there was no expression in CC.
In leprotic samples, weak to moderate positivity was observed
in the cytoplasm of macrophages in all forms and reactions
(13) PTX3: in CC, there was mild and focal expression on
endothelial cells, neural branches, and some mononuclear cells
around capillaries. Staining was present in all leprotic samples,
especially on lymphocytes that composed the granulomas. In R2,
there was expression in neutrophils and intersticial cells (14)
SIGLEC15: the endothelium was positive in melanocytic cells in
the basal layer of the epidermis in CC. In the leprotic samples, it
was expressed in macrophages in all forms and reactional states.
(16) UBD: expression was observed in cells of the inner portion of
the sweat gland excretory duct cells in CC. In leprotic cases, weak
and focal expression was observed inmacrophages of granulomas
of all forms and reactional states, especially in vacuoles inside the
LL macrophages.
DISCUSSION
Analysis of mRNA expression in leprotic skin lesions is complex
since differentially expressed values may vary because of changes
resulting from the disease process and differences in histological
patterns of skin segments. With regard to leprotic lesions,
there are important variations in the extension of inflammatory
infiltration and cellular composition of granulomas usually
associated with different histopathological characteristics of
clinical forms, duration of the disease, and the intensity and
development of reactional states (beginning, well established,
or resolution phase) (Ridley and Jopling, 1966; Hastings
et al., 1988). Furthermore, skin samples with leprosy may
present with a decrease or disappearance of normal skin
structures such as pilo sebaceous follicles, glands, neural
branches, and arrector pili muscles. Thus, these important
variables are difficult to standardize and can change the
RNA expression profile, making it difficult to interpret
the data. However, considering that samples were obtained
from sites with similar histological patterns (trunk and
limbs) is likely that most of the differentially expressed
mRNAs are related to the pathophysiological mechanisms of
leprosy.
The large number of differentially expressed mRNAs found
between disease samples and healthy controls evidence the
complexity of the pathophysiological mechanisms underlying
leprosy at the molecular level and indicate that numerous
genes are involved in establishment of the clinical forms,
besides onset and progression of the reactional forms. It is
clear that a large number of these mRNAs are present in
all forms of the disease spectrum, in spite of variation in
levels of expression, suggesting that most of them comprise a
common pathophysiological mechanism of the disease. However,
some mRNAs are exclusively expressed in certain forms or
specific reactional types. Others, such as GJB2 and KRT6C,
showed inverted expression, i.e., they were up-regulated in
the clinical forms of the disease, but were down-regulated
in the reactional states, or vice versa. These variations of
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FIGURE 3 | Histological sections of skin biopsies stained by IHC. ANGPTL4 expression in neural branches (Schwann cell) and luminal in sweat glands of CC
(A1, IHC x20); strong expression in macrophages in TT granulomas (A2, IHC x10). Weak expression of BAI1 in neural branches of CC (B1, IHC x20) and absence of
granulomas R1 (B2, IHC x20). Weak expression of BCAT1 in sebaceous gland CC (C1, IHC x10) and strong in macrophages of R1 granulomas (C2, IHC x20). CD2
positive in rare lymphocytes around capillaries on the papillary dermis of CC (D1, IHCx40) and large numbers of lymphocytes in the periphery granuloma TT (D2, HCI
x40). CD27 expression in rare lymphocytes around capillaries in the papillary dermis of CC (E1, IHC x100) and large numbers of lymphocytes in the periphery and
inside some TT granulomas (E2, IHCx40). No expression of CD52 in lymphocytes of CC for (F1, IHCx40) and large numbers of lymphocytes in the periphery of R1
granuloma (F2, IHC x40). EML2 expression absent in all skin components in DC (G1, X4 IHC) and weak positivity in macrophages of R2 (G2, IHCx40). FA2H
expressed in sebaceous glands of CC (H1, IHCx10) and macrophage of R1 granulomas (H2, IHCx 40). GZMB expression absent in perivascular lymphocyte of CC
(I1, IHCx40) and finely granular and cytoplasmic positivity in rare lymphocytes in the periphery and inside TT granulomas (I2, IHCx100). Strong LIPA expression in
sebaceous glands of CC (J1, IHC x2) and macrophages of TT granulomas (J2, IHC x 40). Strong MMP9 expression in macrophages of TT and R2 granulomas (K1,
IHCx40, K2, IHCx40). Absent expression of NCF1 in all skin components in CC (L1, IHCx2) and positivity in macrophage of R2 granuloma (L2, IHCx 40). Weak
immunostaining of PTX3 on perivascular cells in CC (M1, IHCx20) and in macrophages, neutrophils, and interstitial cells of R2 (M2, IHCx 40). SIGLEC15 expression in
endothelial cells of CC (N1, IHCx 20) and macrophages in LL (N2, IHCx 40). UBD expression in the inner layer of the excretory duct of sweat gland cells (O1, IHCx 4)
and in vacuoles of macrophage in LL (O2, IHCx 100).
expression are compatible with different clinic pathological
characteristics of leprosy. Being an infectious disease, leprotic
lesions are composed mainly of immune cells at various
degrees of differentiation and therefore present with many
mRNAs common to inflammatory and/or infectious processes.
Furthermore, the cellular composition of granulomas has
some peculiarities, which are characterized by distinct clinic
pathological patterns between the polar groups [(TT + BT) vs.
(LL+ BL)] and the reactional forms (R1 vs. R2). Granulomas on
the tuberculoid side are well defined and composed of epithelioid
macrophages (M1 profile) surrounded mainly by large numbers
of T and B lymphocytes and other cells. On the lepromatous
side, granulomas are diffuse, with vacuolated macrophages (M2
profile) and scarce lymphocytic infiltrates. The reactions also
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FIGURE 4 | Heat map of the 88 mRNAs submitted to RT-PCR validation. Hierarchical unsupervised cluster, with euclidean distance and average linkage of all
samples and differentially expressed gene validated. All samples [controls, clinical forms (TT, BT, BB, BL, LL), R1, and R2] and the 69 genes validated were
submitted to analysis of the unsupervised hierarchical groups, with correlation Pearson metric and average linkage. Samples selected for validation are marked with a *.
have significant differences in cellular composition. In all type
“1” reactional lesions, there is an influx of lymphocytes and
young macrophages (M1 profile) resulting in disorganization of
pre-existing granulomas, edema, and sometimes necrosis. In type
“2” reaction, neutrophils, which are almost absent in the clinical
forms and in the type “1” reaction, are a major component and
commonly form microabscesses (Figure 2). In both reactional
states, vessels and stromal cells undergo important changes.
Therefore, these differences are probably related to particular
expression of some mRNAs in the clinical forms and reactional
episodes.
The complexity of leprosy at the molecular level is also
observed in the numerous signaling pathways involved in
the disease and in the reactional states. The large number
of differentially expressed mRNAs detected in this study,
are also differentially expressed in a number of diseases
such as various cancers (breast, colon, prostate, liver,
pancreas, kidney, central nervous system, etc.), storage
diseases, inflammatory/autoimmune diseases (Crohn’s disease,
psoriasis, ulcerative colitis, and systemic lupus erythematosus),
neurodegenerative (Alzheimer’s disease), infectious diseases
(tuberculosis, other mycobacterial infections and AIDS),
non-infectious granulomatous disease, and others (diabetes
and atherosclerosis). This indicates that leprosy shares
pathophysiologic mechanisms with a large number of non-
neoplastic and neoplastic diseases (Supplement 21). This
explains in part why leprosy can clinically mimic a large number
of these diseases with overlapping clinical and pathological
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features and similar expression of these laboratory markers,
which makes it difficult to diagnose and delays diagnosis for long
periods (Foss and Motta, 2012). For example, leprosy commonly
mimics certain autoimmune diseases such as systemic lupus
erythematosus, psoriasis, and arthritis (Prasad et al., 2013). Data
from literature shows that the mRNAs that we subjected to
RT-PCR validation are related to numerous pathophysiological
processes, mainly immune response, cell proliferation, apoptosis,
angiogenesis, matrix extracellular, damage, and/or neural
repair and lipid metabolism. These processes are regulated
by important signaling pathways. Several of these mRNAs
are involved in regulating the immune response, for example,
NF-κB, TGF-beta superfamily, IL-17, and p53 signaling
are involved in antigen presentation (Supplements 16–18
and 21).
Molecular studies have identified numerous markers that
participate in the pathological processes of cancer and infectious
or inflammatory diseases. These molecules have been the subject
of experimental studies and have also been tested in several
clinical studies. New drugs, such as monoclonal antibodies
(biological) are in testing phase or have already been applied for
the treatment of various diseases (Supplement 21). Even though
important metabolic disorders are caused by such drugs, studies
carried out in cancer, degenerative diseases, and metabolic,
infectious, and genetic disorders, can also contribute to the
discovery of alternative new forms of treatment for leprosy and
its reactional states, based on the assumption that several mRNAs
differentially expressed in leprosy are therapeutic targets for
these diseases. However, specific studies need to be conducted
to evaluate the actual value of these mRNAs in the context
of leprosy. Interestingly, some drugs such as clofazimine and
thalidomide, which are commonly used in leprosy, are also
used for the treatment of neoplastic and non-neoplastic diseases
(Zhou et al., 2013; Koval et al., 2014). Studies demonstrated that
clofazimine can inhibit the cell growth in triple-negative breast
cancer (Koval et al., 2014). Thalidomide, a drug commonly used
to treat type “2” (R2) reactional episodes has been successfully
employed in the treatment of a large number of diseases,
including inflammatory diseases and cancers, such as myeloma
(Zhou et al., 2013).
There are few reports in literature on mRNA expression in
leprosy. In general, studies have shown that genes associated with
negative regulation of the immune system are also associated with
leprosy (Liu et al., 2012; Guerreiro et al., 2013; Orlova et al., 2013;
Singh et al., 2013). Some of these previously described mRNAs,
such as ubiquitin, are also differentially expressed in the present
study (Mehta and Liu, 2014). Ubiquitination is an important
biochemical process that controls many aspects of protein
function such as degradation and protein-protein interaction.
It is also involved in induction of apoptosis, cell cycle control,
and activation of NF-κB (nuclear factor kappa enhancer binding
protein). The transcription factor NF-κB, in turn, controls many
processes including immunity, inflammation, and apoptosis.
The UBD gene was found to be highly expressed in leprosy,
indicating that the ubiquitination is a common process across the
spectrum of the disease, but with higher values in type 1 reaction
(Figure 3O1 and Supplement 19).
Bleharski et al. (2003) evaluated the genes expression in
skin lesions of leprosy patients with the polar forms (six T-
lep and five L-lep), diagnosed according to R&J criteria. They
identified several mRNAs up regulated in T-lep associated
with antigen processing/presentation (UBD, PSMB4, CD1b,
CD28, and CD79a), anti-microbial (cathepsin g and SLP1) and
pro-inflammatory/Th1 (SLAM, Il-1 receptor, IL-15, IL-7, IL12
receptor-beta e lymphotoxin-α). In the L-lep the up regulated
genes were associated with anti-inflammatory/Th2 (TGFß1, IL-5,
and latent TGFß protein-2), inhibitory receptors (SIRP-1α, LIR-
7, LIR-4, LIR3 e LIR8) and B cell response (CD80, Ig heavy chain
gamma 3, CD83, Ig kappa chain, anti-colorretal carcinoma heavy
chain, MD-1, CD22, BLNK, rearranged Ig heavy chain, Ig lambda
locus, Ig kappa light chain variable region, CD19, Ig heavy
chain constant M, TNFRSF17, IgM binding protein 2 and Ig
lambda-like polypeptide 1). In the present study, the comparison
between TT and LL (Supplement 4) did not evidence the same
differentially expressed mRNAs, however, some of these mRNAs
were identified in other comparisons (UBD, SLP1, SLAM, IL15,
TGFß1, CD83, and CD19) like disease vs. CC (Supplement 2).
Other mRNAs identified by Bleharski et al. (2003), though not
related to the mentioned pathways, were identified in the present
study (CD47, FcER1 gamma, IFNα receptor 1, CD14, chitinase 1,
and CD4).
Siddiqui et al., identified in chromosome 10p13 a locus
associated to susceptibility to leprosy in Indian patients (Siddiqui
et al., 2001). In the present study, 2 genes differentially expressed
that are present in the chromosome 10p13 (CCDC3 down-
regulated and CELF2 up-regulated), were observed comparing
disease vs. CC. In the literature, the Coiled-coil domain
containing 3 (CCDC3) represses tumor necrosis factor-α/nuclear
factor κB-induced endothelial inflammation and the CELF2 is
associated with T-cell signaling and it is also a suppressor gene of
colon cancer (Ramalingam et al., 2012; Azad et al., 2014; Mallory
et al., 2015). Studies about the function of both genes in leprosy
are unknown.
Evaluation of protein expression of 15 selected genes by IHC
showed that there was agreement in most of the samples with
the microarray analysis. The same results were obtained for most
up or down-regulated mRNAs detected by the microarray and
validated by RT-PCR and in the detection or lack of protein
expression in the inflammatory infiltrates of leprosy clinical
forms and reaction states (Figure 3). However, some genes
(UBD and GZMB, for example) showed disagreement, where
up-regulation of mRNA was observed in the microarray and
RT-PCR, weak immunostaining or focal inflammatory processes
were seen in leprotic samples subject to IHC. Therefore, small
changes or even conflicting data between microarray gene
expression/RT-PCR and IHC indicates that other regulatory
mechanisms are probably involved in the pathophysiological
processes of leprosy.
In summary, this study shows that leprosy is a complex disease
from the molecular point of view, since a large number of
mRNAs involved in several pathophysiological mechanisms and
signaling pathways are differentially expressed in leprosy related
mainly to antigen presentation pathway, cytotoxic T lymphocyte-
mediated apoptosis of target cells, and B cell development.
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These numerous mRNAs, which are probably involved in the
establishment and progression of the clinical forms of leprosy and
in the reactional episodes, are also reported in numerous other
diseases. These findings open new perspectives that may be used
in the development of new approaches to treat different diseases
and identification of biomarkers with predictive or therapeutic
roles in leprosy.
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